Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda...
December 19, 2024 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty January 2025 Dividend Record and Payment Dates
October 22, 2024 08:00 ET | Source: XOMA Corporation

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
September 23, 2024 06:30 ET | Source: XOMA Corporation

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
June 20, 2024 07:30 ET | Source: XOMA Corporation

XOMA Declares Quarterly Preferred Stock Dividends

July 2024 Dividends
April 03, 2024 09:00 ET | Source: XOMA Corporation

XOMA Corporation Announces Closing of Tender Offer

XOMA completes acquisition of Kinnate.
February 16, 2024 08:00 ET | Source: XOMA Corporation

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition
January 11, 2024 16:05 ET | Source: XOMA Corporation

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA)...
January 08, 2024 07:30 ET | Source: XOMA Corporation

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA appoints Owen Hughes as CEO
December 20, 2023 07:30 ET | Source: XOMA Corporation

XOMA Declares Quarterly Preferred Stock Dividends

January quarterly dividend payment to XOMAP and XOMAO stockholders of record on 1/3/2024

Next Page keyboard_arrow_right